UPMC OPTIMISE-C19 Trial, a COVID-19 Study

NCT04790786 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

4571

Enrollment

OTHER

Sponsor class

Stopped Emergency Use Authorizations for monoclonal antibodies withdrawn

Conditions

Covid19

Interventions

BIOLOGICAL: Lilly Bamlanivimab
BIOLOGICAL: Regeneron Casirivimab + Imdevimab
BIOLOGICAL: Lilly Bamlanivimab + Etesevimab
BIOLOGICAL: Sotrovimab
BIOLOGICAL: Bebtelovimab

Sponsor

Erin McCreary

Collaborators

[object Object]